GET DAILY SIGNALSWhy Is Korro Bio (KRRO) Stock Down -3.96% Today?
Key Takeaways
- KRRO shares fell roughly 3.96% to $13.84 in early trading, extending the prior session's 8.39% decline.
- The primary overhang is Novo Nordisk's (NVO) decision to terminate its research collaboration and license agreement, which erased collaboration revenue and a key source of external validation.
- Secondary pressures include continued cash burn—a $17.55 million third-quarter net loss—and recent Form 144 filings signaling insider selling activity.
- Broader risk-off sentiment in clinical-stage biotech, driven by elevated Treasury yields, is compounding the stock-specific weakness.
- Investors are now watching the ANCHOR Phase 1/2 trial for KRRO-121, the planned KRRO-111 regulatory filing, and upcoming healthcare conferences for catalysts.
- For deeper analysis of Price Targets, Earnings, and Forecast, visit the dedicated KRRO pages.
- Explore Trending AI Robots to see which AI-driven trading strategies are performing best under current market conditions.
Opening Summary
Korro Bio, Inc. (KRRO), a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing RNA-editing genetic medicines, saw its shares fall 3.96% to $13.84 in Thursday's session, down $0.57 from Wednesday's close of $14.41. The decline confirmed a second consecutive day of selling pressure and extended a pullback from the stock's strong year-to-date rally. Market participants pointed to the lingering fallout from the termination of the company's Novo Nordisk (NVO) collaboration, persistent operating losses, and a risk-off tone across speculative biotech as the immediate drivers.
Novo Nordisk Collaboration Termination Weighs on Sentiment
The most significant overhang on KRRO is the formal end of its research collaboration and license agreement with Novo Nordisk (NVO). The partnership, originally focused on cardiometabolic disease targets, had already been paused in late 2025. Its termination removed a key source of collaboration revenue—which fell to zero in the third quarter—and stripped away an external validation signal that had supported the company's broader platform narrative. For a pre-revenue biotech, the loss of a marquee partner weighs disproportionately on investor confidence, even when the company retains full economic rights to its wholly owned programs.
Losses and Insider Selling Add Pressure
Korro Bio (KRRO) remains in a heavy investment phase. The company reported a third-quarter net loss of approximately $17.55 million, or $0.98 per share, alongside rising research and development activity for its lead candidates. While the loss came in narrower than consensus expectations and the company reported $124.8 million in cash, equivalents, and marketable securities—enough to fund operations into the second half of 2028—the continued cash burn keeps the shares sensitive to shifts in risk appetite. Recent Form 144 filings indicating proposed sales of securities by insiders added a further layer of supply-side pressure during the session.
Sector and Macro Headwinds
The decline in KRRO also reflects broader conditions in the clinical-stage biotechnology complex. Rising Treasury yields and a generally cautious tone toward high-beta, cash-burning names have driven risk-off positioning across RNA- and gene-editing-adjacent peers. This backdrop has made it difficult for pre-commercial developers to hold gains even in the absence of fresh company-specific bad news, amplifying the selling in names already under fundamental pressure.
Market Context and Trading Activity
Thursday's move followed an unusually volatile stretch for KRRO. The shares had surged through much of the autumn on momentum from the company's third-quarter update and the start of dosing in the ANCHOR Phase 1/2 trial, before giving back ground sharply this week. Trading volumes have remained active relative to recent averages, reflecting elevated turnover as investors reassess the pipeline and the post-earnings rally. Even after the pullback, the stock remains well above its 52-week low, underscoring the wide trading range that has characterized the name.
What Comes Next for KRRO
Looking ahead, investors will focus on execution across Korro Bio's (KRRO) wholly owned programs. The company expects to begin dosing participants with urea cycle disorders in the second part of the ANCHOR study in the first half of 2027, with interim data anticipated in the second half of 2027. It also plans to submit a regulatory application for KRRO-111, its alpha-1 antitrypsin deficiency candidate, in the first half of 2027. Near-term, appearances at the Jefferies Global Healthcare Conference and other healthcare gatherings could provide incremental updates. Risks remain substantial, however, including clinical execution uncertainty, the absence of collaboration revenue, and an extended path to potential commercialization.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently delivering the strongest performance under prevailing market conditions. Tickeron offers hundreds of bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Only the most robust performers are featured in this dedicated section, helping traders identify strategies aligned with today's market environment. Explore the Trending AI Robots page to see which approaches are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for KRRO turns positive, indicating new upward trend
KRRO saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 70 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for KRRO just turned positive on October 20, 2026. Looking at past instances where KRRO's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 110 of 127 cases where KRRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The 10-day RSI Indicator for KRRO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 46 cases where KRRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KRRO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.498). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement